Back to Search Start Over

Too much tolerance for hyperoxemia in mechanically ventilated patients with SARS-CoV-2 pneumonia? Report from an Italian intensive care unit.

Authors :
Damiani E
Casarotta E
Carsetti A
Mariotti G
Vannicola S
Giorgetti R
Domizi R
Scorcella C
Adrario E
Donati A
Source :
Frontiers in medicine [Front Med (Lausanne)] 2022 Jul 28; Vol. 9, pp. 957773. Date of Electronic Publication: 2022 Jul 28 (Print Publication: 2022).
Publication Year :
2022

Abstract

Background: In COVID-19 patients requiring mechanical ventilation, the administration of high oxygen (O <subscript>2</subscript> ) doses for prolonged time periods may be necessary. Although life-saving in most cases, O <subscript>2</subscript> may exert deleterious effects if administered in excessive concentrations. We aimed to describe the prevalence of hyperoxemia and excessive O <subscript>2</subscript> administration in mechanically ventilated patients with SARS-CoV-2 pneumonia and determine whether hyperoxemia is associated with mortality in the Intensive Care Unit (ICU) or the onset of ventilator-associated pneumonia (VAP).<br />Materials and Methods: Retrospective single-center study on adult patients with SARS-CoV-2 pneumonia requiring invasive mechanical ventilation for ≥48 h. Patients undergoing extracorporeal respiratory support were excluded. We calculated the excess O <subscript>2</subscript> administered based on the ideal arterial O <subscript>2</subscript> tension (PaO <subscript>2</subscript> ) target of 55-80 mmHg. We defined hyperoxemia as PaO <subscript>2</subscript> > 100 mmHg and hyperoxia + hyperoxemia as an inspired O <subscript>2</subscript> fraction (FiO <subscript>2</subscript> ) > 60% + PaO <subscript>2</subscript> > 100 mmHg. Risk factors for ICU-mortality and VAP were assessed through multivariate analyses.<br />Results: One hundred thirty-four patients were included. For each day of mechanical ventilation, each patient received a median excess O <subscript>2</subscript> of 1,121 [829-1,449] L. Hyperoxemia was found in 38 [27-55]% of arterial blood gases, hyperoxia + hyperoxemia in 11 [5-18]% of cases. The FiO <subscript>2</subscript> was not reduced in 69 [62-76]% of cases of hyperoxemia. Adjustments were made more frequently with higher PaO <subscript>2</subscript> or initial FiO <subscript>2</subscript> levels. ICU-mortality was 32%. VAP was diagnosed in 48.5% of patients. Hyperoxemia (OR 1.300 95% CI [1.097-1.542]), time of exposure to hyperoxemia (OR 2.758 [1.406-5.411]), hyperoxia + hyperoxemia (OR 1.144 [1.008-1.298]), and daily excess O <subscript>2</subscript> (OR 1.003 [1.001-1.005]) were associated with higher risk for ICU-mortality, independently of age, Sequential Organ failure Assessment score at ICU-admission and mean PaO <subscript>2</subscript> /FiO <subscript>2</subscript> . Hyperoxemia (OR 1.033 [1.006-1.061]), time of exposure to hyperoxemia (OR 1.108 [1.018-1.206]), hyperoxia + hyperoxemia (OR 1.038 [1.003-1.075]), and daily excess O <subscript>2</subscript> (OR 1.001 [1.000-1.001]) were identified as risk factors for VAP, independently of body mass index, blood transfusions, days of neuromuscular blocking agents (before VAP), prolonged prone positioning and mean PaO <subscript>2</subscript> /FiO <subscript>2</subscript> before VAP.<br />Conclusion: Excess O <subscript>2</subscript> administration and hyperoxemia were common in mechanically ventilated patients with SARS-CoV-2 pneumonia. The exposure to hyperoxemia may be associated with ICU-mortality and greater risk for VAP.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2022 Damiani, Casarotta, Carsetti, Mariotti, Vannicola, Giorgetti, Domizi, Scorcella, Adrario and Donati.)

Details

Language :
English
ISSN :
2296-858X
Volume :
9
Database :
MEDLINE
Journal :
Frontiers in medicine
Publication Type :
Academic Journal
Accession number :
35966865
Full Text :
https://doi.org/10.3389/fmed.2022.957773